Chardan Capital Maintains Buy on Avidity Biosciences, Raises Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae has maintained a Buy rating on Avidity Biosciences (NASDAQ:RNA) and increased the price target from $23 to $33.
March 05, 2024 | 10:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital has reaffirmed its Buy rating on Avidity Biosciences and raised the price target from $23 to $33.
The increase in price target by a reputable analyst like Keay Nakae signals a strong confidence in Avidity Biosciences' future performance. This endorsement is likely to positively influence investor sentiment and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100